Trial result ·
Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This study tested a drug called firsekibart for gout flares. It was for adults who had trouble with NSAIDs, colchicine, or both. These drugs had not worked well, were not tolerated, or could not be used. Each person had at least 2 flares in the past year. The study took place at hospitals in China. For the first 24 weeks, people got firsekibart or compound betamethasone. Neither people nor their doctors knew which drug they got. After that, people could get firsekibart for flares as needed. This later phase lasted until week 48.
What they found
Of 313 people in the first phase, 300 went on to the later phase. By week 48, 70 people on firsekibart had a flare come back. In the betamethasone group, 116 people had a flare come back. The typical wait to a first new flare was 37 days in that group. With firsekibart, this point was not reached during the study. The risk of a new flare was lower with firsekibart. Side effects were about as common in both groups. No new safety concerns came up in the longer follow-up.
What it means for patients
The authors say firsekibart kept cutting down flares that came back. This effect held through 48 weeks. They say its safety stayed steady and good. The study looked at people with few other drug choices.
Why it is not certain yet
In the later phase, everyone knew they got firsekibart. Knowing the drug can affect how people report flares. The study was done only in China. The abstract does not give the quality of life or pain results. It also does not show what happens after 48 weeks.
The registered trial
The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.
Source
Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial.
PubMed · PMID 42154367We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Gout publications